Fig. 6: Regimen-dependent MetaCyc functional reprogramming of the gut microbiome and host immune associations. | Nature Communications

Fig. 6: Regimen-dependent MetaCyc functional reprogramming of the gut microbiome and host immune associations.

From: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial

Fig. 6: Regimen-dependent MetaCyc functional reprogramming of the gut microbiome and host immune associations.

A Differential abundance of MetaCyc pathways between dolutegravir and darunavir/ritonavir treatment arms across study time points (0, 24, 48, and 96 weeks), estimated with ANCOMBC2 (abundance ~ treatment * time_point + covariates + (1 | participant_id), prevalence ≥10%). Points represent estimated log₂ fold changes (dolutegravir − darunavir/ritonavir) and error bars denote 95% confidence intervals. Pathways with q value < 0.05 and confidence intervals excluding zero are highlighted. The adjacent heatmap displays per-time-point log₂ fold changes (dolutegravir − darunavir/ritonavir) and pathway prevalence. Statistics are based on n = 88 independent biological replicates (participants: n = 46 DTG, n = 42 DRV/r) and N = 257 longitudinal observations. B Repeated-measures correlations (rmcorr) between CLR-transformed MetaCyc pathway abundances and host clinical or immunologic markers (CD4, CD8, activated T cell subsets, CRP, IL-6, TNF-α, sCD14, BMI), shown separately for darunavir/ritonavir and dolutegravir. Colors indicate correlation direction and magnitude; black outlines denote significant associations after FDR correction (q value < 0.05).

Back to article page